Read our latest updates & insights

Janssen announces it has discontinued its Ph III LOTUS study of Stelara® (ustekinumab) in Systematic Lupus Erythematosus due to lack of efficacy.

Samsung Bioepis announces the CHMP has adopted a positive opinion for Aybintio® (biosimilar bevacizumab).

AbbVie and Sosei Heptares announce a $409M deal to discover and develop new immunology drugs.  The agreement covers the drug-discovery, development and commercialisation of small-molecule medicines that target autoimmune and inflammatory diseases using the G protein-coupled...

Aptevo Therapeutics announces it will receive quarterly “low single digit” fixed royalty payments from Pfizer (Wyeth) for 7 years from the first launch of Ruxience® (biosimilar rituximab). The original royalty agreement was signed by Trubion Pharmaceuticals whic...

Sandoz launched its ‘Biosimilars Generation’ campaign, aimed to help Canadians better understand the benefits of biosimilars, their safety and efficacy, and the opportunities for cost savings. The campaign includes a new website aimed at supporting and educating...

Ankylosing Spondylitis News reports new data from Germany indicates Simponi® (golimumab) is an effective therapy for people with ankylosing spondylitis and other chronic inflammatory conditions, regardless of pre-treatment with other TNF inhibitors.

Bio-Thera Solutions announces China’s NMPA has accepted its BLA for BAT1706 (proposed bevacizumab biosimilar).

Innovent Biologics announces China’s NMPA has approved Byvasda® (bevacizumab) for the treatment of patients with advanced non-small cell lung cancer and metastatic colorectal cancer in China.

The Centre for Biosimilars reported on a survey presented at a virtual meeting of the European League Against Rheumatism which studied the prescribing habits of French rheumatologists. The survey revealed that many rheumatologists still lack confidence in switching to tumor...